DeepuMadduriMD

PubMed

• 1001 citations
  Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
  Noopur Raje, Jesus G. Berdeja, Yi Lin, David S. Siegel, Sundar Jagannath
  The New England Journal of Medicine. 2019-05-01
• 94 citations
  Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies.
  Adam D Cohen, Samir Parekh, Bianca D Santomasso, Jaime Gállego Pérez-Larraya, Niels W C J van de Donk
  Blood Cancer Journal. 2022-02-24
• 1594 citations
  An inflammatory cytokine signature predicts COVID-19 severity and survival.
  Diane Marie Del Valle, Seunghee Kim-Schulze, Hsin-Hui Huang, Noam D. Beckmann, Sharon Nirenberg
  Nature Medicine. 2020-08-24

Journal Articles

• Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma  
  Nikhil C Munshi, Larry D Anderson, Deepu Madduri, Sagar Lonial, Noopur Raje, Fabio Petrocca, Kristen Hege, The New England Journal of Medicine

Abstracts/Posters

• Translational Analysis from CARTITUDE-1, an Ongoing Phase 1b/2 Study of JNJ-4528 BCMA-targeted CAR-T Cell Therapy in Relapsed and/or Refractory Multiple Myeloma (R/R M...
  Deepu Madduri, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• A Machine Learning Approach Identifies a 30-Gene Model That Predicts Sensitivity to Selinexor in Multiple Myeloma
  Deepu Madduri, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• ADAR1 Drives Disease Progression in Multiple Myeloma By Acting Both As an RNA Editor of Specific Transcripts and As a DNA Mutator of Their Cognate Genes
  Deepu Madduri, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Outcomes in Multiple Myeloma Patients Progressing on Lenalidomide Maintenance
  Deepu Madduri, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Updated Results from an Ongoing Phase 1 Clinical Study of bb21217 Anti-Bcma CAR T Cell Therapy
  Deepu Madduri, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Safety and Preliminary Clinical Activity of REGN5458, an Anti-Bcma x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma
  Deepu Madduri, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Join now to see all

Lectures

• Increased HLA-E Expression Correlates with Early Relapse in Multiple Myeloma 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018